Read our latest advice on Coronavirus (COVID-19)

Our services are open and safe to attend – we are here to help

Industry and our research

NIHR Clinical Research Facility (CRF) at Guy’s and St Thomas’

The NIHR CRF for experimental medicine, hosted by the Trust, provides state of the art facilities and expertise to support the NHS, universities and industry in conducting ground breaking experimental medicine studies. The management and infrastructure of the CRF is embedded within the NIHR Biomedical Research Centre at Guy’s and St Thomas’ and King’s College London.

Our CRF consists of four units; an adult MHRA Phase 1 CRF unit at Guy’s Hospital, and adult, children's and imaging units at St Thomas’ Hospital. Being located across two sites in the heart of London provides us with access to one of the most diverse populations in the UK.

We are uniquely placed to deliver Phase 1 commercial and non-commercial studies. Our CRF is the only one in the UK with embedded Good Manufacturing Practice (GMP) cell manufacturing and immune monitoring platforms.

Our other research platforms include: a stem cell facility, flow and mass cytometry facility, an infectious diseases biobank and an NIHR BioResource.

Key contacts

Industry led trials

Industry funded (but not led)

Why do research at Guy’s and St Thomas’?

We have excellent research facilities as we are home to the National Institute for Health Research (NIHR) Biomedical Research Centre, which is run in partnership with King’s College London, and the NIHR Clinical Research Facility.

The NIHR BRC at Guy’s and St Thomas’ and King’s College London works to develop and deliver new medicines and diagnostics to patients, drive research and innovation into the NHS, and provide national systems leadership for maximum impact to patients. In 2016, the NIHR awarded Guy’s and St Thomas’ and King’s College London £64.4 million over five years so our Biomedical Research Centre can continue its ground-breaking research into innovative new treatments for patients.

We recognise that engaging with industry is key to driving the translational research agenda and biomedical innovations for patient benefit.